Quantitation of intracellular triphosphate of emtricitabine in peripheral blood mononuclear cells from human immunodeficiency virus-infected patients. 1999

A Darque, and G Valette, and F Rousseau, and L H Wang, and J P Sommadossi, and X J Zhou
Department of Clinical Pharmacology, The Liver Center, Center for AIDS Research, University of Alabama at Birmingham, Birmingham, Alabama 35294, USA.

An analytical methodology combining solid-phase extraction (SPE) and high-performance liquid chromatography (HPLC) was developed to quantitate the intracellular active 5'-triphosphate (TP) of beta-L-2',3'-dideoxy-5-fluoro-3'-thiacytidine (emtricitabine) (FTC) in human peripheral blood mononuclear cells (PBMCs). The FTC nucleotides, including 5'-mono-, di-, and triphosphates, were successively resolved on an anion-exchange SPE cartridge by applying a gradient of potassium chloride. The FTC-TP was subsequently digested to release the parent nucleoside that was finally analyzed by HPLC with UV detection (HPLC-UV). Validation of the methodology was performed by using PBMCs from healthy donors exposed to an isotopic solution of [(3)H]FTC with known specific activity, leading to the formation of intracellular FTC-TP that was quantitated by an anion-exchange HPLC method with radioactive detection. These levels of FTC-TP served as reference values and were used to validate the data obtained by HPLC-UV. The assay had a limit of quantitation of 4. 0 pmol of FTC-TP (amount on column from approximately 10(7) cells). Intra-assay precision (coefficient of variation percentage of repeated measurement) and accuracy (percentage deviation of the nominal reference value), estimated by using quality control samples at 16.2, 60.7, and 121.5 pmol, ranged from 1.3 to 3.3% and -1.0 to 4. 8%, respectively. Interassay precision and accuracy varied from 3.0 to 10.2% and from 2.5 to 6.7%, respectively. This methodology was successfully applied to the determination of FTC-TP in PBMCs of patients infected with human immunodeficiency virus after oral administration of various dosing regimens of FTC monotherapy.

UI MeSH Term Description Entries
D007963 Leukocytes, Mononuclear Mature LYMPHOCYTES and MONOCYTES transported by the blood to the body's extravascular space. They are morphologically distinguishable from mature granulocytic leukocytes by their large, non-lobed nuclei and lack of coarse, heavily stained cytoplasmic granules. Mononuclear Leukocyte,Mononuclear Leukocytes,PBMC Peripheral Blood Mononuclear Cells,Peripheral Blood Human Mononuclear Cells,Peripheral Blood Mononuclear Cell,Peripheral Blood Mononuclear Cells,Leukocyte, Mononuclear
D010710 Phosphates Inorganic salts of phosphoric acid. Inorganic Phosphate,Phosphates, Inorganic,Inorganic Phosphates,Orthophosphate,Phosphate,Phosphate, Inorganic
D012015 Reference Standards A basis of value established for the measure of quantity, weight, extent or quality, e.g. weight standards, standard solutions, methods, techniques, and procedures used in diagnosis and therapy. Standard Preparations,Standards, Reference,Preparations, Standard,Standardization,Standards,Preparation, Standard,Reference Standard,Standard Preparation,Standard, Reference
D002851 Chromatography, High Pressure Liquid Liquid chromatographic techniques which feature high inlet pressures, high sensitivity, and high speed. Chromatography, High Performance Liquid,Chromatography, High Speed Liquid,Chromatography, Liquid, High Pressure,HPLC,High Performance Liquid Chromatography,High-Performance Liquid Chromatography,UPLC,Ultra Performance Liquid Chromatography,Chromatography, High-Performance Liquid,High-Performance Liquid Chromatographies,Liquid Chromatography, High-Performance
D003841 Deoxycytidine A nucleoside component of DNA composed of CYTOSINE and DEOXYRIBOSE. Cytosine Deoxyribonucleoside,Cytosine Deoxyriboside,Deoxyribonucleoside, Cytosine,Deoxyriboside, Cytosine
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000068679 Emtricitabine A deoxycytidine analog and REVERSE TRANSCRIPTASE INHIBITOR with antiviral activity against HIV-1 and HEPATITIS B viruses. It is used to treat HIV INFECTIONS. Beta-L-2',3'-dideoxy-5-fluoro-3'-thiacytidine,Coviracil,Emtriva,Beta L 2',3' dideoxy 5 fluoro 3' thiacytidine
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D000837 Anion Exchange Resins High-molecular-weight insoluble polymers that contain functional cationic groups capable of undergoing exchange reactions with anions. Anion Exchange Resin,Anion Exchangers (Resins),Exchange Resin, Anion,Exchange Resins, Anion,Resin, Anion Exchange,Resins, Anion Exchange
D000998 Antiviral Agents Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. Antiviral,Antiviral Agent,Antiviral Drug,Antivirals,Antiviral Drugs,Agent, Antiviral,Agents, Antiviral,Drug, Antiviral,Drugs, Antiviral

Related Publications

A Darque, and G Valette, and F Rousseau, and L H Wang, and J P Sommadossi, and X J Zhou
February 2008, Antimicrobial agents and chemotherapy,
A Darque, and G Valette, and F Rousseau, and L H Wang, and J P Sommadossi, and X J Zhou
January 2003, Antimicrobial agents and chemotherapy,
A Darque, and G Valette, and F Rousseau, and L H Wang, and J P Sommadossi, and X J Zhou
December 1999, Antimicrobial agents and chemotherapy,
A Darque, and G Valette, and F Rousseau, and L H Wang, and J P Sommadossi, and X J Zhou
January 2002, Antimicrobial agents and chemotherapy,
A Darque, and G Valette, and F Rousseau, and L H Wang, and J P Sommadossi, and X J Zhou
April 1990, Journal of clinical microbiology,
A Darque, and G Valette, and F Rousseau, and L H Wang, and J P Sommadossi, and X J Zhou
July 1994, Antimicrobial agents and chemotherapy,
A Darque, and G Valette, and F Rousseau, and L H Wang, and J P Sommadossi, and X J Zhou
October 1998, Antimicrobial agents and chemotherapy,
A Darque, and G Valette, and F Rousseau, and L H Wang, and J P Sommadossi, and X J Zhou
January 1995, The Journal of infectious diseases,
A Darque, and G Valette, and F Rousseau, and L H Wang, and J P Sommadossi, and X J Zhou
December 1996, The Journal of general virology,
A Darque, and G Valette, and F Rousseau, and L H Wang, and J P Sommadossi, and X J Zhou
July 2009, Journal of neurovirology,
Copied contents to your clipboard!